Skye Bioscience, Common Stock Annual Yield
| SKYE Stock | USD 4.28 0.21 4.68% |
Skye Bioscience, Common fundamentals help investors to digest information that contributes to Skye Bioscience,'s financial success or failures. It also enables traders to predict the movement of Skye Stock. The fundamental analysis module provides a way to measure Skye Bioscience,'s intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Skye Bioscience, stock.
Skye | Annual Yield |
Skye Bioscience, Common Company Annual Yield Analysis
Skye Bioscience,'s Yield generally refers to the amount of cash that is paid back to the owner of a security over a specific time (usually one year). It is expressed as a percentage of current market price, and usually amounts to all the interests and/or dividends paid over a given period. A higher yield allows the shareholders to generate returns on their investments sooner. However, investors should also be aware that a high yield may be a result of market turmoil or increased price volatility.
Skye Annual Yield Driver Correlations
Understanding the fundamental principles of building solid financial models for Skye Bioscience, is extremely important. It helps to project a fair market value of Skye Stock properly, considering its historical fundamentals such as Annual Yield. Since Skye Bioscience,'s main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Skye Bioscience,'s historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Skye Bioscience,'s interrelated accounts and indicators.
Click cells to compare fundamentals
Small firms, start-ups, or companies with high growth potential typically do not pay out dividends or distribute a lot of their profits. These companies will have small yield. Alternatively, more established companies, ETFs, and funds that invest in bonds will have higher yields.
| Competition |
In accordance with the recently published financial statements, Skye Bioscience, Common has an Annual Yield of 0.0%. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Did you try this?
Run AI Portfolio Architect Now
AI Portfolio ArchitectUse AI to generate optimal portfolios and find profitable investment opportunities |
| All Next | Launch Module |
Skye Bioscience, ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Skye Bioscience,'s sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Skye Bioscience,'s managers, analysts, and investors.Environmental | Governance | Social |
Skye Fundamentals
| Return On Equity | -0.55 | ||||
| Return On Asset | -0.3 | ||||
| Current Valuation | 62.63 M | ||||
| Shares Outstanding | 30.34 M | ||||
| Shares Owned By Insiders | 1.89 % | ||||
| Shares Owned By Institutions | 85.41 % | ||||
| Number Of Shares Shorted | 1.99 M | ||||
| Price To Book | 1.71 X | ||||
| EBITDA | (13.55 M) | ||||
| Net Income | (37.64 M) | ||||
| Cash And Equivalents | 2.93 M | ||||
| Cash Per Share | 0.01 X | ||||
| Total Debt | 4.62 M | ||||
| Debt To Equity | 0.84 % | ||||
| Current Ratio | 0.91 X | ||||
| Book Value Per Share | 2.50 X | ||||
| Cash Flow From Operations | (13.95 M) | ||||
| Short Ratio | 5.76 X | ||||
| Earnings Per Share | (3.60) X | ||||
| Target Price | 18.0 | ||||
| Number Of Employees | 11 | ||||
| Beta | 1.75 | ||||
| Market Capitalization | 163.52 M | ||||
| Total Asset | 11.94 M | ||||
| Retained Earnings | (104.38 M) | ||||
| Working Capital | (2.25 M) | ||||
| Net Asset | 11.94 M |
About Skye Bioscience, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Skye Bioscience, Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Skye Bioscience, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Skye Bioscience, Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Skye Bioscience, Common is a strong investment it is important to analyze Skye Bioscience,'s competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Skye Bioscience,'s future performance. For an informed investment choice regarding Skye Stock, refer to the following important reports:Check out Skye Bioscience, Piotroski F Score and Skye Bioscience, Altman Z Score analysis. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Skye Bioscience,. If investors know Skye will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Skye Bioscience, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.60) | Return On Assets (0.30) | Return On Equity (0.55) |
The market value of Skye Bioscience, Common is measured differently than its book value, which is the value of Skye that is recorded on the company's balance sheet. Investors also form their own opinion of Skye Bioscience,'s value that differs from its market value or its book value, called intrinsic value, which is Skye Bioscience,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Skye Bioscience,'s market value can be influenced by many factors that don't directly affect Skye Bioscience,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Skye Bioscience,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Skye Bioscience, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Skye Bioscience,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.